Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | HTR3A | P46098 | 6/20 | 0.53 |
| ▸ | CACNA1G | O43497 | 4/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13091102 | 0.87 | HSD17B10 (0.70) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091071 | 0.81 | MAPT (0.73) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091041 | 0.81 | HTR3A (0.77) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL12793634 | 0.80 | ALDH1A1 (0.68) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091039 | 0.79 | HTR3A (0.78) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091055 | 0.79 | ALDH1A1 (0.67) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091052 | 0.79 | HTR3A (0.78) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13091144 | 0.78 | ALDH1A1 (0.69) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL17242569 | 0.72 | MEN1 (0.58) | ESR1MAPTKDM4EHSD17B10HTT | |
| SCHEMBL13090998 | 0.72 | KMT2A (0.79) | ESR1MAPTKDM4EHTTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. | 2010-10-21 | — | — | US | disclosed |
| WO-2009023558-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | VM DISCOVERY INC. (US) | 2009-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267671-A1 | COMPOSITIONS AND METHODS FOR APOPTOSIS MODULATORS | BAX, BCL2, BAD | ESR1 3313/4885MAPT 2663/4885KDM4E 3186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.